Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sirolimus-eluting collagen implant for AV fistula outcomes
NCT02513303Phase 3Completed
- Sponsor
- Vascular Therapies
- Start
- Nov 2015
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of sirolimus in arteriovenous fistula (AVF) (2 arms), sponsored by Vascular Therapies. Primary endpoint: Fistula Suitability for Dialysis at 6 Months. Started Nov 2015; status: completed.
02
Drugs
sirolimus
03
Conditions
arteriovenous fistula (AVF)
Beyond the preview
Go deeper on NCT02513303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02513303.